What is Lee's Pharmaceutical Holdings Limited (LPCUF)?

Lee's Pharmaceutical Holdings Limited (LPCUF) is a stock in the Healthcare sector, Medical - Pharmaceuticals industry. View full analysis on Stocks360.

What is the current price of LPCUF?

The current price of LPCUF is $0.19. Prices are updated in real time on Stocks360.

What is LPCUF's price-to-earnings (PE) ratio?

LPCUF's trailing twelve-month PE ratio is 3.64, based on current price and earnings per share data available on Stocks360.

What is LPCUF's market capitalization?

LPCUF's market capitalization is $112,055,366.00, placing it in the small-cap tier.

Does LPCUF pay a dividend?

Yes. LPCUF has a trailing twelve-month dividend yield of 0.06%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Lee's Pharmaceutical Holdings Limited (LPCUF)

Stock analysis · OTC · Healthcare · Medical - Pharmaceuticals

$0.19

Market Cap

$112.06M

PE (TTM)

3.64

EPS (TTM)

N/A

Dividend Yield

5.63%

Beta

0.60

Day Range

$0.19 – $0.20

52-wk Range

$0.19 – $0.20

Avg Volume

N/A

Volume

6.00K

Lee's Pharmaceutical Holdings Limited (LPCUF) is a publicly traded company in the Healthcare sector. Latest price: $0.19. Market cap $112.06M. Trailing PE 3.64. Dividend yield 5.63%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $0.19 2026-10-26 · $0.19 (+1.12%)

Earnings

Next Earnings

Mar 30, 2027

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the dist…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	3.64×
P/S (TTM)	0.31×
P/B	0.29×
PEG	0.06×
P/FCF (TTM)	1.47×
EV / EBITDA	1.74×
EV / Sales	0.25×
Earnings Yield	27.58%
Free Cash Flow Yield	68.14%
Dividend Yield	5.63%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$491.95M
Revenue (TTM)	$1.94B
Net Income (TTM)	$167.27M
Free Cash Flow (TTM)	$240.74M
Net Debt	-$114.55M
Working Capital	$72.05M
Gross Margin	53.75%
Operating Margin	-0.40%
Net Margin	8.64%
Return on Equity	8.02%
Return on Invested Capital	-0.21%